![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Calypso Medical Technologies |
---|---|
Information provided by: | Calypso Medical Technologies |
ClinicalTrials.gov Identifier: | NCT00123838 |
The purpose of this study is to evaluate a non-ionizing electromagnetic method to align the prostate treatment site for radiation therapy and to monitor its position throughout radiation therapy delivery. The clinical study involves using an investigational device, the Calypso® 4D Localization System, and requires permanent implantation of three small sensors called Beacon® transponders in the prostate.
Condition | Intervention |
---|---|
Prostate Cancer |
Device: Calypso® 4D Localization System |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Beacon® Transponder Implantation and Localization in the Prostate |
Estimated Enrollment: | 50 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | February 2008 |
The goal for prostate radiation therapy is to give a high dose of radiation to the prostate and a minimal dose to the healthy tissue around the prostate. It is well known that the prostate moves slightly within the pelvis and that its position varies a few millimeters from day to day. There are several methods used to position the body and the prostate accurately at the beginning of each radiation therapy session.
One of the standard methods is to permanently implant small markers (gold spheres or cylinders) in the prostate and use x-rays in the radiation therapy treatment room to determine whether the markers are in the correct position. If the markers are in the correct position, then the assumption is that the prostate also is in the correct position. If the markers are not in the correct position on the x-ray, then the table that the patient lies on can be shifted so that the markers are in the right place.
In this study the Beacon® transponder will be used in place of the standard gold marker. During the radiation therapy visits, the patient position in the treatment room will be corrected using the Beacon transponder with an investigational system, called the Calypso® 4D Localization System. The Calypso system consists of a flat panel, placed over the pelvis and connected to a computer, which monitors the position of the Beacon transponders within the prostate. During five radiation therapy appointments and one extra visit, the position of the markers in the prostate will be confirmed with x-rays.
The Beacon transponder is a small glass cylinder that contains a tiny electrical circuit. The glass vial is completely sealed and separates the internal components (i.e., the electrical circuit) from the rest of the body.
The glass vial is approximately one-third of one inch long and one-tenth of one inch in diameter. Three Beacon transponders will be implanted in the prostate. They will be permanently implanted.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Scottsdale Healthcare - Osborn | |
Scottsdale, Arizona, United States, 85260 | |
United States, California | |
Sharp Memorial Hospital | |
San Diego, California, United States, 92123 | |
United States, Florida | |
M.D. Anderson Cancer Center Orlando | |
Orlando, Florida, United States, 32806 | |
United States, Nebraska | |
The Nebraska Medical Center | |
Omaha, Nebraska, United States, 68105 | |
United States, Ohio | |
The Cleveland Clinic | |
Cleveland, Ohio, United States, 44192 |
Study Director: | Lisa Levine, Ph.D. | Calypso Medical Technologies |
Responsible Party: | Calypso Medical Technologies ( Lisa Levine, PhD/Sr Director, Clinical Affairs ) |
Study ID Numbers: | Prostate Stage 3 |
Study First Received: | July 22, 2005 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00123838 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Prostate Cancer Radiotherapy Neoplasm |
Localization Tracking Cancer of Prostate Neoplasms, Prostate |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |